Sunday, September 15 will be the decisive day of this PDC tournament, with the quarterfinals, semifinals and final all taking place. The quarters get underway first in the afternoon session ...

Lantheus may have been hoping that “statistically significant” phase 3 data for its radioligand therapy would make a splash at ESMO, but not everyone is impressed. The biotech used the ...

Novartis’s Pluvicto (lutetium vipivotide tetraxetan) was already approved in this setting in 2023 after positive results from its Phase III VISION trial. The majority of the results presented at ...

While Lutathera was the first of its radionuclides to reach the market, Novartis’ flagship therapy is Pluvicto (lutetium lu177 vipivotide tetraxetan), which was approved by the FDA for PSMA ...

Elsewhere in mHSPC, Novartis is trying to pair its radioligand therapy Pluvicto with ADT and androgen receptor-directed therapy like Nubeqa in the phase 3 PSMAddition trial. That study is ...

The advent of targeted radiopharmaceuticals is revolutionising the field of oncology. These innovative therapies integrate systemically delivered radiotherapy into diagnostic and personalised ...

From Danielle Fishel and Rick Steves announcing their diagnosis to the “Emily in Paris” star discussing her cancer experience, here’s what’s happening in the oncology space this week. I wrote this ...

Although the number of tournaments has remained the same, the prize pool has gone up significantly. The PDC has made as much as £3,750,000 in prize money available for the floor tournaments. At each ...

Novartis’ Lutathera and Pluvicto are leading the market, with expected sales of $4 billion by 2027. Companies like Eli Lilly and Bristol Myers Squibb are investing in in-house production ...

Novartis’s Pluvicto (lutetium vipivotide tetraxetan) was already approved in this setting in 2023 after positive results from its Phase III VISION trial. The FDA is likely to look favourably on ...